Thursday 16 October, 2025
Objectives: Tumor cells can exploit host immune checkpoints to allow them to evade eradication by the immune system. For several…
Read moreAbstracts
Physiologically based pharmacokinetic modeling approach to assess drug-drug interactions (DDI) between psychopharmaceuticals – focus on mirtazapine and venlafaxine
Thursday 16 October, 2025
Introduction: In clinical and ambulatory care, drugs are often combined to improve the efficacy of the therapy. Especially the combination…
Read moreApplication of Physiologically Based Pharmacokinetic (PBPK) Modelling to Support First in Human dose selection.
Thursday 16 October, 2025
Objectives: GLPG1205 is a novel, potent and selective antagonist of G protein-coupled receptor 84 (GPR84), activated by medium chain fatty…
Read moreComputing Optimal Drug Dosing with OptiDose: Implementation in NONMEM
Thursday 16 October, 2025
Objectives: Determining “optimal” drug dosing for a target population is still a complex, laborious and qualitative rather than quantitative task….
Read moreComputing Optimal Drug Dosing with Constraints on Model States in NONMEM
Thursday 16 October, 2025
Objectives: Recently, we implemented the optimal drug dosing algorithm OptiDose [1] in NONMEM [2] utilizing standard commands. This allows users…
Read moreModeling inflammatory biomarker dynamics in human LPS challenge studies using delay differential equations
Thursday 16 October, 2025
Objectives: Bacterial infections and sepsis are associated with production of several inflammatory mediators including cytokines such as tumor necrosis factor α…
Read moreA system pharmacology Boolean network model for the TLR4-mediated host response in early sepsis
Thursday 16 October, 2025
Objectives: Sepsis is a life-threatening condition driven by the dysregulated host immune response to an infection, in which the activation…
Read morePopulation pharmacokinetic modelling in Ewing sarcoma patients focussing on etoposide as an example
Thursday 16 October, 2025
Introduction: Ewing sarcoma is a very aggressive bone tumour, which often occurs in adolescents or young adulthood [1]. The incidence…
Read morePredictive performance of a parasite growth dynamics model for the evaluation of anti-malarial drugs: a case study with mefloquine
Thursday 16 October, 2025
Objectives: A semi-mechanistic pharmacokinetic-pharmacodynamic (PKPD) model was developed to help screen antimalarial compounds in the pre-clinical phase [1]. Assuming that…
Read moreExtrapolation of the early bacterial activity of pretomanid to inform dose selection for the treatment of pulmonary tuberculosis
Thursday 16 October, 2025
INTRODUCTION A limitation in antitubercular (anti-TB) drug development remains the empiricism based on which companion drugs and their dosing regimens…
Read more